Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.
Bruce Levine: Ten-Year Outcomes Reinforce the Durability of CD19 CAR T-Cell Therapy
oncodaily - Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, shared a post on X: “NEW – Ten-Year Outcomes after CAR T-Cell Therapy for […]
AI Summary: Long‑term data reveal that CD19 CAR‑T therapy produces durable remissions in a subset of B‑cell lymphoma patients, with ten‑year outcomes reinforcing the treatment's long‑term benefit for some. The findings bolster CAR‑T’s curative potential while underscoring the need to identify who will enjoy durable responses.
AACR Report on Cancer Disparities and Health Equity
oncodaily - American Association for Cancer Research (AACR) shared a post on LinkedIn: “The AACR Cancer Disparities Progress Report 2026 is now available. The report outlines the myriad factors that drive and […]
AI Summary: The American Association for Cancer Research released a progress report detailing persistent gaps in cancer outcomes across race, ethnicity, socioeconomic status and geography. It documents uneven access to screening, trials and treatments, calls for targeted funding, workforce diversity and policy fixes, and urges measurable equity goals—because apparently pointing out the problem is step one.
- AACR report release and leadership outreach (4)
- Policy push: briefings, funding calls, and trial equity (4)
AACR report release and leadership outreach
Policy push: briefings, funding calls, and trial equity
Novel electronic health record-based marker can identify at-risk transplant patients and reduce organ rejection
medicalxpress - A new multicenter study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that a novel electronic health record-based marker can help clinicians identify transplant patients at high risk for organ rejection because they are not ta…
AI Summary: Teams developed and validated an electronic‑health‑record derived marker that flags transplant recipients at elevated risk of organ rejection. The tool integrates routinely collected clinical data to trigger earlier review and intervention, promising to reduce rejection events if deployed thoughtfully within clinical workflows rather than buried in another alert pile.
Teclistamab Significantly Improves Survival Among Patients with Multiple Myeloma Who Previously Received One To Three Lines of Treatment
esmo - Findings from the MajesTEC-9 study
AI Summary: Clinical data show teclistamab significantly improves survival for patients with multiple myeloma after one to three prior therapies. Those results have ignited discussions about moving the bispecific antibody earlier in treatment algorithms and prompted labs and clinicians to reassess sequencing strategies across relapsed and refractory myeloma.
FDA approves Welireg with pembrolizumab for renal cell carcinoma
medicalxpress - The U.S. Food and Drug Administration has approved Merck's Welireg (belzutifan) in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the adjuvant treatment of renal cell carcinoma in adults with a clear ce…
AI Summary: The FDA cleared Welireg (belzutifan) in combination with pembrolizumab for adjuvant treatment of renal cell carcinoma at high risk of recurrence after surgery. The approval expands belzutifan’s indications, offering a new post‑nephrectomy option intended to lower recurrence risk and reflecting regulators’ willingness to endorse targeted therapy combinations in kidney cancer.
Hibernation-like cooling after stroke may reduce brain damage
medicalxpress - Our body loves the state of homeostasis, where everything is in perfect equilibrium, from temperature to pH levels to fluid balance. As soon as the body's core temperature drops below 95°F (35°C) and stays there for a long time, the heart, nervous system …
AI Summary: Researchers report that inducing a hibernation-like state via drugs and controlled cooling can reduce brain damage after ischemic stroke in preclinical and early clinical work, limiting infarct size, dampening inflammation and improving functional outcomes. The approach shows translational potential but requires carefully designed trials to confirm safety and efficacy.
Rishabh Jain: What ALTAIR Teaches Us About ctDNA-Positive CRC
oncodaily - Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X: “ctDNA-positive CRC after curative surgery sounds like the perfect place to intervene. But ALTAIR says: not so fast. Phase 3, double-blind […]
AI Summary: Coverage examines ALTAIR, a randomized phase‑3 trial testing post‑adjuvant chemotherapy for patients with resected colorectal cancer who are ctDNA‑positive. Experts dissect trial design, endpoints and implications for ctDNA‑guided treatment decisions, debating whether circulating tumor DNA should steer adjuvant therapy or remain an elegant biomarker with stubborn practical hurdles.
E. Anders Kolb: Blood Cancer United Preserves Access to Luveltamab Tazevibulin for Children with AML
oncodaily - E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared a post on LinkedIn: “Today we announced a first‑of‑its‑kind intervention from a nonprofit. Blood Cancer United has stepped up […]
AI Summary: A nonprofit stepped into a supply crisis and purchased the remaining stock of an experimental agent to preserve access for children with acute myeloid leukemia. The emergency buy protects current patients from treatment interruption while stakeholders scramble for a durable manufacturing or regulatory fix, illustrating how charities sometimes act like pharma’s safety net.
Ultrasensitive blood test predicts head and neck cancer relapse months earlier
medicalxpress - A new study by investigators from Mass General Brigham Cancer Institute has found that an ultrasensitive blood test called HPV-DeepSeek could help identify which people with HPV-associated head and neck cancer still had cancer cells in their bodies after …
AI Summary: Researchers validated an ultrasensitive HPV whole‑genome sequencing blood assay that detects minimal residual disease after surgery for HPV‑positive head and neck cancer, flagging relapse months before clinical signs. Early detection could enable earlier salvage therapy and closer surveillance, potentially changing follow‑up care and improving outcomes for this patient group.
First-Ever Dual Vaccine for Lassa Virus and Rabies Deemed Safe in Human Trial
discovermagazine - Learn more about Lassa virus, which continues to ravage parts of West Africa, and how combining a vaccine against it with rabies protection could address two major health concerns at once.
AI Summary: A first-in-human phase 1 trial of an adjuvanted, inactivated rabies virus–vectored Lassa vaccine met safety and tolerability endpoints in healthy adults, generating immune responses that support further development. The combined platform aims to protect against both Lassa fever and rabies, advancing toward larger trials and evaluation in regions where both diseases are endemic.
Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
Richard E. Pratley / nature - Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04440-4In the phase 2 EMBRAZE study, participants receiving tirzepatide and apitegromab lost less lean mass compared to participants receiving tirzepatide and placebo.
AI Summary: A randomized, double‑blind phase 2 trial found apitegromab helped preserve lean mass in people losing weight on tirzepatide (a GLP‑1–class obesity medication). The drug reduced treatment‑associated muscle wasting without undermining weight loss, positioning apitegromab as a potential adjunct for patients worried about strength and frailty during aggressive metabolic therapy.
Florian Lordick Elected ESMO President 2029–2030
oncodaily - Professor Florian Lordick has been elected President of the European Society for Medical Oncology for the 2029–2030 term, marking a new leadership chapter for one of the world’s leading oncology […]
AI Summary: Florian Lordick will serve as ESMO president for 2029–2030, pledging to prioritise precision oncology, workforce development and stronger European collaboration. Colleagues praise his vision for translating research into practice and amplifying policy advocacy; expectations include initiatives to close care gaps and bolster international partnerships — because someone has to herd this many oncologists.
Julie Gralow: Mobile App Symptom Monitoring Helps Maintain Quality of Life in Advanced Cancer
oncodaily - Julie Gralow, Chief Medical Officer of the American Society of Clinical Oncology, shared a post on X: “Use Of Mobile App For Proactive Symptom Monitoring Helped Patients With Advanced Cancer […]
AI Summary: A smartphone-based symptom monitoring program preserved quality of life for people with advanced cancer by enabling real‑time reporting and prompt clinician response. The intervention maintained patient function and well‑being compared with usual care, demonstrating a scalable, low‑cost way to keep symptoms under control — because yes, your phone can sometimes do what clinic schedules cannot.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer
oncodaily - The NRG-GY018 trial returned to the ASCO 2026 stage with the question that matters more than any progression endpoint: do patients actually live longer? Presented by Ramez N. Eskander, MD […]
AI Summary: Updated results from the NRG‑GY018 trial show adding pembrolizumab to chemotherapy sustains an overall survival benefit in advanced endometrial cancer. The follow‑up confirms the durability of immunotherapy’s impact and supports integrating checkpoint inhibitors into standard regimens for eligible patients, potentially changing practice for a cancer type that’s long hungered for better systemic options.
Short-term fasting could boost chemo response in ovarian cancer, study suggests
medicalxpress - A simple change in meal timing may help improve outcomes for women with the most common and aggressive form of ovarian cancer, a new study suggests.
AI Summary: ASCO‑presented research indicates short‑term fasting around chemotherapy cycles can enhance response in high‑grade serous ovarian cancer versus a regular diet, altering tumor biology to increase chemosensitivity. The findings suggest a low‑cost adjunct to standard treatment, though real‑world feasibility and longer‑term benefits require larger trials — fasting as a potential therapeutic booster, not a fad.
First AI-designed 'universal vaccine' tested in humans: UK researchers
medicalxpress - A vaccine targeting a broad range of viruses that was designed using artificial intelligence had a "modest" effect on immune systems in a small, early trial, according to a new study.
AI Summary: UK researchers have initiated the first human trial of a vaccine designed using artificial intelligence, aiming for broad protection beyond conventional strain-specific shots. Early-phase testing focuses on safety and immune responses, marking a novel fusion of machine learning and immunology that could speed vaccine design — if the algorithms behave.
Implanted radiation device cuts brain tumor recurrence: 5 study notes
Ella Jeffries / beckershospitalreview - An implanted radiation device has improved tumor control and overall survival compared with standard radiation therapy in patients with newly diagnosed operable brain metastases, according to phase 3 clinical trial data presented May 30 at the American So…
AI Summary: Clinical trial data show an implanted "tile" radiation device placed at resection sites lowers local recurrence risk for patients with brain metastases. The approach provides a targeted, intraoperative boost that shortens treatment timelines — and gives surgeons one more tool to argue they cured something before the tumor disagreed.
15-strain live biotherapeutic product or same donor fecal microbiota transplant for recurrent Clostridioides difficile infection: a randomized phase 1b trial
Lukas Bethlehem / nature - Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the sam…
AI Summary: A randomized phase 1b trial compared a defined 15‑strain live biotherapeutic product with traditional donor fecal microbiota transplant for recurrent Clostridioides difficile infection and found comparable safety and efficacy. The result supports a manufactured, standardized microbiome therapy as a realistic alternative to donor stool, simplifying logistics and regulation — and making “poop pills” slightly less artisanal.
FDA Approves Oral Combination of Decitabine and Cedazuridine Tablets with Venetoclax for Newly Diagnosed AML
esmo - Evidence for efficacy is based on the results from the Study ASTX727-07
AI Summary: The FDA has approved an oral combination (decitabine/cedazuridine plus venetoclax) as a treatment option for newly diagnosed acute myeloid leukemia patients who are older or unfit for intensive therapy. The approval offers an at-home alternative to frequent infusions, potentially reducing clinic visits and improving convenience for a vulnerable population.
- Experts celebrate all-oral AML option online (3)
- FDA approval and ASCERTAIN V trial evidence (3)
- Targeted therapies and regimen optimization in AML (3)